SOUTHBOROUGH, MA – May 2, 2016 – Veristat, a full service Clinical Research Organization (CRO), announced today that it is expanding its clinical research offerings into Europe through the acquisition of UK-based CRO, Spero Oncology. Spero Oncology is a UK-based CRO specializing in providing clinical operations support for oncology clinical trials primarily throughout Europe, but also in Australia and New Zealand. With the acquisition of Spero Oncology, Veristat now offers its clients full clinical operations support in Europe including feasibility studies, legal representation in the European Union, Clinical Monitoring, Project Management, Protocol Writing and Regulatory Strategy.
May 1, 2016
Veristat Ranked #35 on Boston Business Journal’s “Fast 50” List, the Top 50 Fastest Growing Private Companies in Massachusetts
April 24, 2016
Veristat Recognized as One of the Top 50 Fastest-Growing Private Companies in Massachusetts
Veristat, a full service Clinical Research Organization (CRO), announced today that it has been recognized as one of the top 50 fastest-growing private companies in Massachusetts, taking the #35 slot. According to Privco[i], there are over 4,000 private firms operating in Massachusetts today.
Veristat Named as One of the Fastest Growing Private Companies in Massachusetts by Boston Business Journal
April 6, 2016
Veristat joins the Boston Business Journal’s 2016 Fast 50 (Formerly Pacesetters) list. This is the list of the fastest growing private companies in Massachusetts.
Veristat Strengthens Senior Management Team: Appoints Faith Haines Kolb as Vice President, Biometrics
March 8, 2016
SOUTHBOROUGH, MA – March 08, 2016 – Veristat, a full service Clinical Research Organization (CRO), announced today the appointment of Faith Haines Kolb to the newly created position Vice President of Biometrics. Faith joins Veristat with over 20 years of experience leading operational teams and large-scale projects during periods of rapid growth and international expansion for both large and small CROs. As Vice President of Biometrics, Faith will lead and continue to grow the Biostatistics and Programming teams, as well as the Data Management and Data Standards groups at Veristat.
Veristat participates in Cycle for Survival 2016 and raises over $20,000 to fund rare cancer research.
March 1, 2016
On Saturday, February 27th, Team Veristat JOINED THE BATTLE with Cycle for Survival 2016! Team Veristat had riders at both the Boston, MA and Palo Alto, CA events. In Boston, over 900 riders participated in this amazing, fun and inspiring event! Across the country in 2016 alone, over twenty million dollars has been raised to fund rare cancer research.
February 10, 2016
January 18, 2016
Veristat Supports the Upcoming Boston Cycle for Survival Event
Join Veristat in the Fight Against Rare Cancers: Donate Today!
Veristat to Assist Cidara with Its Trials for Novel Echinocandin Antifungal CD101
September 15, 2015
Veristat Assists EndoCeutics with NDA Submission for Intravaginal Prasterone